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Abstract: Cyclosporine (CYA) is used to preventing ocular attacks in Behçet’s disease patients. 
Yet there are inter-individual variations in efﬁ  cacy. In order to analyze the relationship between 
CYA ﬂ  uctuation with treatment effectiveness and genetic factors, an association of area under 
the plasma concentration time at 0–4 hours (AUC0-4) values and polymorphism for multidrug 
resistance 1 (MDR1) and cytochrome3A5 (CYP3A5) genes was investigated. Genomic DNA 
was collected from 17 Japanese patients with Behçet’s disease. MDR1 polymorphisms were 
determined by direct sequencing from ampliﬁ  ed products for promoter and two exons regions 
and CYP3A5 polymorphisms were analyzed using polymerase chain reaction and restriction 
fragment length polymorphism (PCR-RFLP) method. AUC0-4 value was determined by the 
trapezoidal rule from the data of 5 times blood sampling at 0–4 hours. The haplotype 2 in the 
promoter region of MDR1 inﬂ  uenced signiﬁ  cantly lower AUC0-4 values, implying absorption 
decline of CYA. The CYP3A5 polymorphisms had no direct inﬂ  uence on the effectiveness 
for CYA treatment. In the relation of CYA and AUC0-4 in the patients, 7 cases were grouped 
effective and 4 ineffective. Though there was no difference in dosage, the trough values for 
AUC0-4 were higher in the effective group compared to the ineffective group.
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Introduction
The four main symptoms of Behçet’s disease are recurrent oral aphthosis, skin lesions 
such as erythema nodosum, uveoretinitis, and genital ulcers. 20,000 patients have 
been diagnosed with Behçet’s disease in Japan; however, including the latent, the 
actual number is estimated higher. It is thought to be a multifactorial disease strongly 
associated with a certain genetic background and triggered by the involvement of an 
environmental factor. Studies show strong association of the gene HLA-B51 with 
the disease as a genetic factor (Mizuki et al 2000). Behçet’s disease, also known as 
“Silk Road disease,” being common in Mongoloids along the Silk Road, and rare 
in Caucasians, is thought to have environmental exposures to something around the 
Silk Road as a factor. Cyclosporine (CYA) is effective in preventing ocular attacks in 
Behçet’s disease patients, usually administered at the dosage of 5.0 mg/kg per day. Yet 
there are inter-individual variations in efﬁ  cacy (Fujino et al 1999). In blood level moni-
toring of CYA, the trough level is most commonly used for its convenience, although 
AUC is considered most efﬁ  cacious. However in organ transplantation, with the 
development of cyclosporine micro emulsion preparation, a new monitoring parameter 
is being evaluated as a possible alternative to trough level monitoring. The inter-
individual variations of CYA is the most signiﬁ  cant at 1–3 hours after administration; 
furthermore, the T-cell calcineurin inhibitor effect of CYA correlates with the CYA 
blood level at 2 to 3 hours from administration, suggesting the clinical signiﬁ  cance 
of AUC0-4 (Keown 1999; Mahalati et al 1999; Johnston et al 2000; Levy et al 2002). 
On the other hand, CYA has been reported to be the substrate of P-glycoprotein (Saeki Clinical Ophthalmology 2007:1(3) 298
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et al 1993). MDR1 protein has been reported to function-
ally express P-glycoprotein widely in normal tissue such 
as gastrointestinal epithelial cells, renal proximal tubules, 
luminal capillary bile ducts of the liver, cerebral capillary 
endothelial cells, choroid plexus epithelial cells (Thiebaut 
et al 1987; Sugawara et al 1988). In the gastrointestinal 
tract, P-glycoprotein is expressed in the brush border side, 
and CYA, digoxin, saquinavir which are good substrates 
of P-glycoprotein, are discharged from the gastrointestinal 
epithelial cells into the lumen of the gastrointestinal tract, 
resulting in reduced drug absorption (Fromm 2000). The 
MDR1 gene which codes P-glycoprotein is reported to 
have more than 20 SNPs, including intron and promoter 
region (Hoffmeyer et al 2000; Tanabe et al 2001; Marzolini 
et al 2004). Allele difference inﬂ  uences quantity in protein 
expression, suggesting the difference in drug absorption. 
MDR1 expression is especially small in homozygotes with 
cytosine to thymine mutation and homozygotes with gua-
nine to thymine or guanine to adenine mutations in 2677th 
base of the exon 21, accelerating the absorption of CYA 
(Balram et al 2003; Chowbay et al 2003), however another 
report that in a healthy subject, C3435T mutation in exon 
26 has no effect in the drug conductor of CYA (Min and 
Ellingrod 2002). Also, studies show the polymorphism of 
CYP3A5 affects the clearance of CYA signiﬁ  cantly (Yates 
et al 2003; Min et al 2004). Therefore in order to analyze 
the relationship between CYA interindividual ﬂ  uctuation and 
genetic factors in Behçet’s disease patients, AUC0-4 values, 
polymorphisms for MDR1 and CYP3A5 retrieved, and rela-
tionship with treatment effectiveness was investigated.
Materials and methods
Subjects
The subjects were 17 patients who had been diagnosed 
Behçet’s disease, and had been administered CYA at 
either Yokohama City University Hospital Department of 
Ophthalmology or Hokkaido University Hospital Department 
of Ophthalmology (Table 1). Judgment of effectiveness was 
possible in 11 cases. When the number of attacks during 
six months after the initial administration was half or less 
the number of attacks during six months before the initial 
administration, the case was evaluated effective. All patients 
and control subjects agreed to a blood examination conducted 
according to the guidelines of the Declaration of Helsinki.
CYA blood level
5 times blood sampling, at before, 1, 2, 3 and 4 hours after 
administration of CYA, and levels were measured using 
AxSYM-Cyclosporine- II ⋅ Dynapack (Abbott Japan). 
AUC0-4 value was determined by the trapezoidal rule from 
the 5 time blood sampling data at 0–4 hours.
MDR1 typing
In examination of MDR1 polymorphisms, variants in 
position 2677 of exon 21 (G2677A/T), variants in posi-
tion 3435 of exon 26 (G3435T), and promoter region were 
tested. In examination of MDR1 gene promoter region 
polymorphisms, in accordance with reports by Takane and 
colleagues (2004), PCR was carried out using the primer 
pair 5′-GGAGCAAAGAAATGGAATACAATA-3′, 
5′TTCTCCCGTGAAGACCAAGTTC-3′ and in addition to 
the two previous 5′CTTATGAACATAGAGGAAATAGG-3′ 
and 5′-TGTAGCTCACGCCTGTAATCC-3′ were used 
as sequence primers in sequence reaction using BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems). Using Applied Biosystems 3130 Genetic Analyzer or 
ABI® 377 Genetic Analyzer, base sequence of the ampliﬁ  ed 
genes were determined to assume the haplotype of the 
promoter region.
G2677A/T and G3435T were typed in accordance with 
reports by Tanabe and colleagues (2002).
CYP3A5
CYP3A5 typing was carried out in accordance with report by 
Fukuen and colleagues (2002) for CYP3A5*1, CYP3A5*3, 
CYP3A5*6 using the PCR-RFLP method.
Statistical analysis
Effective and ineffective groups of CYA, AUC0-4 value, 
the correlation of AUC0-4 with each polymorphism were 
evaluated by Student’s t-test.
Results
AUC0-4 monitoring
As with transplantation patients, the AUC0-4 level showed 
higher correlation with C2 level (r2 = 0.80, p  0.001) than 
Table 1 Background characteristics of patients
Gender 
 Male    14
 Female    3
CYA Dose    4.3 ± 1.2 mg/kg 
 Effective    7
 Ineffective    4
 Nonjudgment    6
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trough level (r2 = 0.44, p = 0.035). The trough values were 
signiﬁ  cantly higher, but AUC0-4 and C2 values were not for 
effective groups of CYA (Table 2).
CYP3A5 polymorphisms
2 out of 17 subjects had homozygous CYP3A5*3/*3, 
and 15 had heterozygous CYP3A5*1/*3. AUC0-4 values 
were 2486 ± 952 ng ⋅ hr/ml in those with CYP3A5*3/*3, 
1390 ± 349 ng ⋅ hr/ml in those with CYP3A5*1/*3. 
AUC0-4 values standardized by dosage values were 
614 ± 233 ng ⋅ hr/ml and 354 ± 38 ng ⋅ hr/ml (p = 0.146). 
CYP3A5*1/*3 tended to have lower AUC0-4. However this 
was thought to have no direct inﬂ  uence on the effective-
ness because of majority of patients being CYP3A5*3/*3 
(Table 3).
MDR1 polymorphisms
The polymorphisms of MDR1 promoter region were 
examined to ﬁ  nd neither the deletion at –1423a and –1132a 
nor mutation at –824a and –755a in the 17 subjects. In 
conformity with reports by Takane and colleagues (2004), 
haplotype was estimated from SNP types –1517a, –1459a, 
–1017a, –41a, –145, –129. Of the estimated haplotypes 
9 cases were found to be 1/1, 3 cases 1/2, 2 cases 1/4, and 
1 case each 1/5, 1/6, 2/4 (Table 4). Of the mutations in the 
2677th base of exon 21 of MDR1, 8 cases were found to be 
G/G wild-type, 5 cases G/T heterozygote, 3 cases T/T mutant, 
and one case A/A mutant. Of the polymorphisms found in the 
3435th base of exon 26, 7 cases were G/G wild-type, 7 cases 
G/T heterozygote, 3 cases T/T mutants (Table 5).
MDR1 polymorphisms and AUC0-4 values
The effect of MDR1 polymorphisms on AUC0-4 stan-
dardized by dosage was examined. AUC0-4 values were 
449 ± 195 ng ⋅ hr/ml in those with C/C wild-type in the 
G3435T, 666 ± 256 ng ⋅ hr/ml in those with C/T heterozy-
gote, 704 ± 142 ng ⋅ hr/ml in those with T/T homozygote. 
C homozygotes tended to have lower AUC0-4 than other 
types (p = 0.101, p = 0.079) (Figure 1).
In terms of the G2677A/T, AUC0-4 values were 
485 ± 206 ng ⋅ hr/ml in G/G homozygotes, 523 ± 189 ng ⋅ hr/ml 
in G/T heterozygotes, 856 ± 122 ng ⋅ hr/ml in T/T, A/A 
homozygotes. T/T and A/A which are mutant homozygotes 
had higher AUC0-4 than G/G which is a wild-type (Figure 2). 
This does not disagree with previous reports.
In terms of promoter region polymorphisms, types 1/1, 
1/4, 1/6 had relatively high AUC0-4, while types 1/2, 1/5, 
2/4 had relatively low AUC0-4. Heterozyogotes of haplo-
type 1/2 had signiﬁ  cantly lower AUC0-4 values compared 
to types 1/1 and 1/4 (p = 0.007, 0.049) (Figure 3). Also, all 
four subjects possessing haplotype 1/2 or 2/4 showed wild-
type homozygotes at 3435th and 2677th.
Discussion
Although there was no signiﬁ  cant difference between the 
two groups in dosage at 4.3 ± 1.3 mg/kg/day and 4.3 ± 
1.4 mg/kg/day, trough levels, AUC0-4, C2 tended to be higher 
in those of the effective group than those of the ineffective 
group (Table 2). The fact that T-cell calcineurin inhibitor effect 
correlates well with the CYA blood levels 2–3 hours post-dose 
CYA indicates that AUC0-4 is clinically signiﬁ  cant3–6. The cor-
relation coefﬁ  cient (r2) of AUC0-4 to trough and C2 were 0.44 
(p = 0.035) and 0.80 (p  0.001). C2 showed a higher positive 
Table 3 CYP3A5 genotype and the effectiveness in each patient
Patient no  Evaluation  AUCO-4/dose  CYP3A5
1 Effective  846  *3/*3
2 Effective  732  *3/*3
3 Effective  840  *3/*3
4 Effective  327  *1/*3
5 Effective  492  *3/*3
6 Effective  716  *3/*3
7 Effective  286  *3/*3
8 Ineffective  1024  *3/*3
9 Ineffective  222  *3/*3
10 Ineffective  506  *3/*3
11 Ineffective  308  NT
12 Nonjudgement  551  *3/*3
13 Nonjudgement  730  *3/*3
14 Nonjudgement  636  *3/*3
15 Nonjudgement  831  *3/*3
16 Nonjudgement  490  *3/*3
17 Nonjudgement  381  *1/*3
Abbreviation: NT; not tested.
Table 2 Cyclosporine dosage and pharmacokinetics parameters of each patient group
 Dosage  C0    C2  AUC0-4  AUC0-4/
 (mg/kg/day)  (ng/ml)  (ng/ml)  (ng  ⋅ hr/ml)  dose
Effective 4.3  ± 1.3  110 ± 42  900 ± 490  2474 ± 1090  605 ± 336
Ineffective 4.3  ± 1.4  56 ± 16  579 ± 251  1857 ± 650  515 ± 360
  p = 0.986   p = 0.037  p = 0.259  p = 0.335  p = 0.622Clinical Ophthalmology 2007:1(3) 300
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correlation with AUC0-4, suggesting C2 to be a possible 
efﬁ  cacy alternative to AUC0-4 in Behçet’s disease patients. 
However in this study, although the AUC0-4 of the effective 
group tended to be higher than AUC0-4 of the ineffective 
group, the signiﬁ  cance of this difference is questionable. One 
patient with high AUC0-4 4231 ng ⋅ hr/ml later developed a 
side effect in the central nervous system presumably owing 
to CYA. Additional cases must be evaluated in order to reveal 
effective AUC0-4 and C2 levels.
It has been reported that certain CYP3A5 alleles express 
different CYA metabolic activity, consequently possibly 
effecting CYA blood levels greatly enough to alter the 
curative effect of CYA (Yates et al 2003; Min et al 2004). In 
the present study when efﬁ  cient group and inefﬁ  cient group 
were investigated for CYP3A5 polymorphisms, one case in 
the efﬁ  cient group had CYP3A5*1/*3 heterozygote, others 
in the efﬁ  cient group had CYP3A5*3 homozygote with no 
protein expression. Low AUC0-4 values were shown in 
CYP3A5*1/*3 group. However it was hard to obtain geno-
typic inﬂ  uence of CYP3A5 to AUC0-4 values, because all 
15 patients except for two were CYP3A5*3/*3.
No signiﬁ  cant differentiation was shown between the 
two groups indicating the low possibility that CYP3A5 gene 
directly affects the efﬁ  cacy of CYA.
Concerning the effect of MDR1 polymorphism, Hoffmeyer 
and colleagues (2000) have investigated Caucasian MDR1 
polymorphisms in which the 3435th base mutate from C to T, 
revealing that the P-glycoprotein expression in the intestine 
of patients with CC genotype is less than half of those with 
TT genotype, that alimentary tract MDR1 expression is low 
and digoxin AUC high in TT subjects.
The clearance of CYA is signiﬁ  cantly greater in patients 
with allele mutations to T than in patients with wild-type 
homozygotes (Yates et al 2003). On the other hand, it has 
been reported that MDR1 gene expression is limited and CYA 
absorption is accelerated in homozygote mutations from C to 
T and homozygote mutations of base 2677 of exon 21 (Hoff-
meyer et al 2000; Tanabe et al 2001) and that mutation in the 
3435th base of exon 26 in healthy subjects has no effect on the 
dynamics of CYA (Marzolini et al 2004). Also, Anglicheau 
and colleagues (2004) reported that effect vary between race, 
Table 4 Promoter haplotype of MDRI gene in 17 Japanese Behçet’s disease patients
Patient no  −129  −145  −41a  −1017a  −1459a  −1517a Haplotype
1 T  C  A  T  G/A  T  1/4
2 T  C  A  T  G  T  1/1
3 T  C  A  T  G  T  1/1
4 C/T  C  A/G  C/T  G/A  C/T  2/4
5 T  C  A  T  G  T  1/1
6 T  C  A  T  G  T  1/1
7 C/T  C  A/G  C/T  G  C/T  1/2
8 T  C  A  T  G  T  1/1
9 T  C  A/G  T  G/A  T  1/5
10 T  C  A  T  G  T  1/1
11 C/T  C  A/G  C/T  G  C/T  1/2
12 T  C  A  T  G/A  T  1/4
13 T  C  A  T  G  T  1/1
14 T  C  A  T  G  T  1/1
15 T  C/G  A  T  G/A  T  1/6
16 T  C  A  T  G  T  1/1
17 C/T  C  A/G  C/T  G  C/T  1/2
Table 5 Dose normalized cyclosporine AUC(0-4) and MDR1 
polymorphism in each patient
Patient AUC0-4/  Promoter G2677 C3435T
no dose haplotype  (AT)
1 846 1/4  G/G  C/C
2 732 1/1  G/G  C/T
3 840 1/1  T/T  C/T
4 327 2/4  G/G  C/C
5 492 1/1  G/T  C/C
6 716 1/1  G/T  C/T
7 286 1/2  G/G  C/C
8 1024  1/1  A/A  C/T
9 222 1/5  G/T  C/T
10 506  1/1  G/G  C/C
11 308  1/2  G/G  C/C
12 551  1/4  G/T  T/T
13 730  1/1  T/T  T/T
14 636  1/1  G/T  C/T
15 831  1/6  T/T  T/T
16 490  1/1  G/G  C/T
17 381  1/2  G/G  C/CClinical Ophthalmology 2007:1(3) 301
Effect of MDR1 polymorphisms to cyclosporine AUC0-4 in Behçet’s disease patient
furthermore, SNPs T-129C, C1236T, G2677AT, and 
C3435T of MDR1 have no great impact on pharmacokinetics 
of CYA. In Asian heart transplantation patients, Chowbay 
investigated SNPs C1236T, G2677TA, and C3435T for 
effect on CYA pharmacokinetics, and suggested that not 
genotypes but haplotypes of each should be examined 
(Chowbay et al 2003). Concerning polymorphisms of the 
promoter region in Japanese and Caucasian subjects, there 
were greater MDR1 mRNA expressions in the placenta and 
liver of Japanese heterozygous haplotypes 1/2, 1/3 (Takane 
et al 2004).
In the present study, MDR1 polymorphisms in Japanese 
Behçet’s disease patients were investigated to reveal that in 
genetic region SNP patients possessing alleles with replace-
ment from C to T in base 3435 in exon 26 tended to have 
a high AUC(0-4) level but no signiﬁ  cant difference. Also, 
MDR1 mutations in base 2677 of exon 21 which posses G 
(G/G, G/T) compared to those which do not posses G (A/A, 
A/T) had signiﬁ  cantly higher AUC(0-4) levels. (Figure 2)
Concerning promoter region polymorphisms, types 1/1, 
1/4 and 1/6 had high AUC0-4 levels, types 1/2, 1/5, 2/4 had 
low AUC0-4 levels, and heterozygote of haplotype 1/2, com-
pared to 1/1 and 1/4 had signiﬁ  cantly lower AUC0-4 levels 
(p = 0.007, 0.049) (Figure 3). Out of the ﬁ  ve patients who 
showed low AUC0-4 levels, 4 patients had promoter region 
haplotypes which posses 2 and bases of 3435 and 2677 were 
wild-type homozygote. Thereupon, 10 C3435T homozygote 
subjects were investigated (Table 6). Out of 7 who possessed 
CC, 4 patients had promoter haplotype which posses 2 and 3 
patients did not. The promoter haplotype of three out of three 
patients whose C3435T genotype was T/T did not possess 
2. Out of those who do not possess promoter haplotype 
2, the three CC patients showed AUC0-4 value of 615 ± 
200 ng ⋅ hr/ml, and the three T/T patients showed AUC0-4 
value of 704 ± 142 ng ⋅ hr/ml. It can be said that there was 
no signiﬁ  cant difference between C3435T genotypes when 
there is no promoter haplotype 2 possession (p = 0.56). On 
the other hand, the four promoter haplotype 2 possessors 
whose C3435T genotype was CC showed AUC0-4 value 
of 326 ± 41 ng ⋅ hr/ml. This was signiﬁ  cantly lower in 
comparison to the AUC0-4 values of promoter haplotype 
2 nonpossessors whose C3435T genotype is CC and promoter 
haplotype 2 nonpossessors whose C3435T genotype is T/T 
(p = 0.034, 0.003).
These ﬁ  ndings suggested the necessity of investigation 
of MDR1 gene polymorphisms, including promoter region 
haplotypes.
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Figure 1 Correlation of the MDR1 exon 26 SNP with dose normalized cyclosporine AUC0-4. AUC0-4 values were 449 ± 195 ng ⋅ hr/ml in those with C/C in the 
C3435T, 666 ± 256 ng ⋅ hr/ml in those with C/T, 704 ± 142 ng ⋅ hr/ml in those with T/T genotype. C homozygotes tended to have lower AUC0-4 than other types. 
(p = 0.101, p = 0.079).
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Figure 2 Correlation of the MDR1 exon 21 SNP with dose normalized cyclosporine AUC(0-4). AUC(0-4) values were 485 ± 206 ng ⋅ hr/ml in G/G genotype, 523 ± 
189 ng ⋅ hr/ml in G/T genotype, 856 ± 122 ng ⋅ hr/ml in T/T, A/A genotype, T/T and A/A which are mutant homozygotes had higher AUC0-4 than G/G genotype. (p = 0.008, 0.019).
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Figure 3 Correlation of the MDR1 promoter region polymorphisms with dose normalized cyclosporine AUC0-4. Promoter types 1/1, 1/4, and 1/6 had high AUC0-4 levels, 
types 1/2, 1/5, 2/4 had low AUC0-4 levels, and heterozygote of haplotype 1/2, compared to 1/1 and 1/4 had signiﬁ  cantly lower AUC0-4 levels. (p = 0.007 and 0.049).
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